Hepatocellular Carcinoma PD-L1 Stability and Immunotherapy Response Data

A research article analyzing PD-L1 protein regulation in hepatocellular carcinoma across human tissues, mouse models, and cell lines. The study, authored by Luca Grisetti and published on figshare in 2026, found PD-L1 was increased in ~60% of tumors and identified subtype-dependent stability influencing immune checkpoint inhibitor efficacy. It includes results from functional assays with primary immune cells and treatments like durvalumab and atezolizumab.

Use Cases

• Training predictive models for immunotherapy response based on PD-L1 expression and molecular subtype features mentioned in the description
• Analyzing the relationship between PD-L1 glycosylation, protein stability, and immune cell cytotoxicity as described in the results
• Benchmarking drug performance (e.g., durvalumab vs. atezolizumab) in co-culture assays with donor-dependent response profiles
• Studying tumor-immune microenvironment interactions in virally driven hepatocellular carcinoma contexts

Strengths

• Includes data from multiple sources: human HCC tissues, a transgenic mouse model, and five HCC cell lines representing distinct molecular subtypes.
• Functional assay results are based on co-cultures with primary activated PBMCs from multiple healthy donors.
• PD-L1 analysis covers expression, glycosylation, stability, and turnover assessed via Western blot, flow cytometry, and immunohistochemistry.

Limitations

• The dataset is a 1.5 MB PDF document; underlying raw data tables or matrices are not directly provided.
• Row and column counts are unknown, limiting assessment of data scale and structure.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Experimental analysis of human and mouse tissues and cell lines using biochemical profiling, functional co-cultures, and drug treatments.

Freshness

Last updated 2026-05-01 05:27:34; freshness should be verified.